MacroGenics announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the FDA\u2019s accelerated approval of TZIELD.<\/p>\n
The approval covers TZIELD for delaying the decline in endogenous insulin production in children aged eight to 17 years who were recently diagnosed with stage 3 type 1 diabetes.<\/p>\n
MacroGenics said the approval expands the therapeutic potential of TZIELD as a disease-modifying therapy for type 1 diabetes.<\/p>\n
Under the terms of MacroGenics\u2019 agreement with Sanofi, the recent FDA approval triggered the $24.5 million regulatory milestone payable to MacroGenics.<\/p>\n
MacroGenics remains eligible to receive up to $305 million in additional milestone payments. The company also retains the right to receive a single-digit royalty on global net sales above a specified annual threshold.<\/p>\n
TZIELD, also known as teplizumab, is a CD3-directed monoclonal antibody. It was first approved in the U.S. in November 2022 to delay the onset of stage 3 type 1 diabetes in adults and children eight years and older diagnosed with stage 2 type 1 diabetes.<\/p>\n
In April 2026, the FDA expanded the indication to include children aged one year and older. TZIELD is also approved in adults and children eight years and older with stage 2 type 1 diabetes in several international markets.<\/p>\n
MacroGenics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company develops product candidates through its proprietary antibody-based technology platforms and has entered into several strategic collaborations with global pharmaceutical and biotechnology companies.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"MacroGenics announced that it will receive a $24.5 million regulatory milestone payment from Sanofi following the FDA\u2019s accelerated…\n","protected":false},"author":2,"featured_media":40295,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[27527,13012],"class_list":["post-40294","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-macrogenics","tag-sanofi"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/40294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=40294"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/40294\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/40295"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=40294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=40294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=40294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}